Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555854 | 0.78 | GSR (0.43) | — | |
| Cysteine SCHEMBL19359143 | 0.73 | PTGS1 (0.52) | PTGS1SLC7A11 | |
| Cysteine SCHEMBL19359142 | 0.73 | PTGS1 (0.52) | PTGS1SLC7A11 | |
| SCHEMBL28616609 | 0.71 | KDM4E (0.30) | — | |
| Cysteine SCHEMBL1889352 | 0.69 | PTGS1 (0.46) | PTGS1SLC7A11 | |
| SCHEMBL6022461 | 0.69 | — | — | |
| SCHEMBL11880209 | 0.69 | — | — | |
| SCHEMBL3794407 | 0.68 | CASP3 (0.35) | PTGS1 | |
| SCHEMBL8909319 | 0.68 | — | — | |
| Cysteine SCHEMBL16208953 | 0.66 | PTGS1 (0.61) | PTGS1SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097222-A1 | CELL DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | claimed |
| EP-2987805-A2 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE | IPSEN PHARMA S.A.S. (FR) | 2016-02-24 | — | — | EP | claimed |
| US-20150252093-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES | IPSEN PHARMA S.A.S. (FR) | 2015-09-10 | — | — | US | claimed |
| US-20150175665-A1 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | IPSEN PHARMA S.A.S. (FR) | 2015-06-25 | — | — | US | claimed |
| US-8999940-B2 | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal | IPSEN PHARMA S.A.S. (FR) | 2015-04-07 | — | — | US | claimed |
| US-20110136725-A1 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | BIOMEASURE, INCORPORATED | 2011-06-09 | — | — | US | claimed |
| EP-2328922-A2 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE | IPSEN PHARMA S.A.S. (FR) | 2011-06-08 | — | — | EP | claimed |
| EP-2323678-A2 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES | IPSEN PHARMA S.A.S. (FR) | 2011-05-25 | — | — | EP | claimed |
| EP-2320923-A2 | TRUNCATED ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE | IPSEN PHARMA S.A.S. (FR) | 2011-05-18 | — | — | EP | claimed |
| EP-2318433-A2 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | IPSEN PHARMA S.A.S. (FR) | 2011-05-11 | — | — | EP | claimed |
| WO-2010016940-A2 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE | IPSEN PHARMA S.A.S. (FR) | 2010-02-11 | — | — | WO | claimed |
| WO-2010016935-A2 | TRUNCATED ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE | IPSEN PHARMA S.A.S. (FR) | 2010-02-11 | — | — | WO | claimed |
| WO-2010016938-A2 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES | IPSEN PHARMA S.A.S. (FR) | 2010-02-11 | — | — | WO | claimed |
| WO-2010016944-A2 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | IPSEN PHARMA S.A.S. (FR) | 2010-02-11 | — | — | WO | claimed |
| WO-2010016936-A1 | PHARMACEUTICAL COMPOSITIONS OF ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE | IPSEN PHARMA S.A.S. (FR) | 2010-02-11 | — | — | WO | claimed |
| WO-2023097222-A1 | CELL DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-2323678-B1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES | IPSEN PHARMA SAS (FR) | 2016-03-23 | — | — | EP | disclosed |
| WO-2010016940-A2 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE | IPSEN PHARMA S.A.S. (FR) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016935-A2 | TRUNCATED ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE | IPSEN PHARMA S.A.S. (FR) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016944-A2 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | IPSEN PHARMA S.A.S. (FR) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252093-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES | GIPR, GPR119, GLP1R | PTGS1 2005/4885SLC7A11 1213/4885 |
| US-20150175665-A1 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | GIPR, GPR119, GLP1R | PTGS1 2525/4885SLC7A11 1071/4885 |
| US-20110136725-A1 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | GIPR, GPR119, GLP1R | PTGS1 2539/4885SLC7A11 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.